Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.

Thérèse Dix-PeekBoitumelo P PhakathiEunice J van den BergCaroline DickensTanya N AugustineHerbert CubaschAlfred I NeugutJudith S JacobsonMaureen JoffePaul RuffRaquel A B Duarte

Published in: Breast cancer research and treatment (2023)

We suggest that the Ki67 be changed to a cutoff of 20-25% in our population to better reflect the luminal subtype classifications. This change would inform treatment options for breast cancer patients in settings where genomic assays are unaffordable.

Keyphrases

high throughput
copy number
neoadjuvant chemotherapy